Enoxaparin is indicated for use in both treatment and prophylaxis settings which means it can be used in many therapy areas by a wide range of specialists.

Enoxaparin is used to prevent and treat thromboembolic diseases, and is usually administered by injection by either GP, nurse or the patient themself.

In the UK, enoxaparin is approved for five indications:

The prophylaxis of thromboembolism disorders of venous origin, in particular those which may be associated with orthopaedic surgery.
The prophylaxis of venous thromboembolism (VTE) in medical patients bedridden due to acute illness.
The treatment of venous thromboembolism disease (VTED) presenting with deep vein thrombosis (DVT), pulmonary embolism (PE) or both.
The treatment of unstable angina (UA) and non-Q-wave myocardial infarction (NQMI), administered concurrently with aspirin.
The prevention of thrombus formation in the extracorpreal circulation during haemodialysis.

Side effects

Bleeding
Pain, bruising or irritation; hard, inflamed nodules or an itchy red rash at the injection site
Symptoms similar to those of hayfever
Abdominal/chest pain
Headache

Read more at Wikipedia.org

• [List your site here Free!]



	Enoxaparin sodium-induced bullous pemphigoid-like eruption: a report of two cases The authors present a 62-year-old woman and a 31-year-old man whom developed paralysis of their lower extremities secondary to epidermal hematomas overlying ... From Journal of Drugs in Dermatology, 9/1/04

	Subcutaneous Enoxaparin in the Treatment of DVT - deep vein thrombosis Deep venous thrombosis (DVT) is often treated in the hospital with five to 10 days of unfractionated heparin. The activated partial thromboplastin time ... From American Family Physician, 9/15/01 by Richard Sadovsky

	Enoxaparin treatment in unstable coronary artery disease: international cost savings - communications to the editor To the Editor: We wish to challenge the statement in the review of antithrombotic agents for use in coronary artery disease by Cairns et al (1(p241S)) ... From CHEST, 2/1/02

	Congenital Hypoplasia of the Inferior Vena Cava: An Underappreciated Cause of Deep Venous Thromboses among Young Adults This report illustrates how newer imaging techniques are identifying vasculopathies as risk factors for deep venous thrombosis (DVT). In this case, a healthy young man presented with a straightforwar From Military Medicine, 9/1/05 by Lane, David A

	A new radiologic appearance of pulmonary thromboembolism : multiloculated pleural effusions The objective of this study was to describe the clinical course and response to treatment of five patients who developed loculated pleural effusions ... From CHEST, 7/1/04 by Levent Erkan

	How much do you know about anticoagulant therapy? Guide staff members to better management of patients receiving antithrombotic medications. Abstract: Review necessary management techniques regarding safe use of anticoagulant therapy. There's been a From Nursing Management, 2/1/04 by Wimberley, Paige

	Controversies in timing of the first dose of anticoagulant prophylaxis against venous thromboembolism after major orthopedic surgery Adjusted doses of oral warfarin sodium or fixed doses of subcutaneous low-molecular-weight heparin (LMWH) are the standard approaches for preventing ... From CHEST, 12/1/03 by Gary E. Raskob

	Treat DVT with low molecular weight heparin Deep vein thrombosis (DVT) and pulmonary embolism (PE) are costly and common problems in the United States. The clinical consequences of DVT include fatal ... From Nurse Practitioner, 10/1/03 by Nadeau, Cheryl

Home

Contact

Resources

Exchange Links

ebay